Quantcast

Industry news that matters to you.  Learn more

Archives for October 2017

Recently Identified Biomarker Could Be Valid Diagnostic Tool for Gaucher Disease, Mouse Study Suggests

Glucosylsphingosine (lyso-Gb1), a recently identified biomarker for Gaucher disease (GD), was shown to contribute to the development or peripheral symptoms in a mouse study, potentially validating its use as a diagnostic tool, according to new research. The study, “Glucosylsphingosine Causes Hematological and Visceral Changes in Mice—Evidence for a Pathophysiological Role in Gaucher Disease,” was published in the International Journal of Molecular Sciences.

So My Brain Amyloid Level is “Elevated”—What Does That Mean?

Testing drugs to prevent or delay the onset of Alzheimer’s dementia and using them in the clinic will mean identifying and informing adults who have a higher risk of Alzheimer’s but are still cognitively normal. A new study from the Perelman School of Medicine at the University of Pennsylvania has shed light on how seniors cope with such information.

New Study: Videssa Breast Blood Test Can Effectively Rule Out Breast Cancer, Regardless of Breast Density

A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer by Provista Diagnostics, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue. Nearly half of all women in the U.S. have dense breast tissue.

Tyme Identifies Potential Method and Biomarker for Converting Malignant Tumors to Inert Calcified Mass

Tyme Technologies, Inc. (Nasdaq: TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced it has identified a mechanism and related biomarker that the Company believes could potentiate the calcification of tumors. During clinical evaluation of the Company’s lead product candidate, it was observed that subsequent to SM-88 therapy some lytic bone lesions converted to benign sclerotic bone. Following further examination, the Company believes it has isolated the cause of this conversion and developed a treatment method that can be used in combination with SM-88 to cause calcification of tumors with a particular biomarker. The Company has conducted a small number of tests in canine osteosarcoma and observed positive results, including a rapid ossification of tumors.

Immunovia Signs Major Autoimmune Biomarker Discovery Collaboration with Linkoping University

Immunovia announced today the signing of a major research collaboration on discovery of diagnostic biomarkers for autoimmune diseases with the Faculty of Medicine and Health Sciences, Linkoping University. The collaboration aims to accelerate the development of a new generation of diagnostic tests based on Immunovia’s leading IMMray™ antibody array platform.